Shareholder Alert: Ademi LLP investigates whether Evoqua Water Technologies Corp has obtained a Fair Price in its transaction with Xylem
MILWAUKEE, Jan. 23, 2023 /PRNewswire/ -- Ademi LLP is investigating Evoqua (NYSE: AQUA) for possible breaches of fiduciary duty and other violations of law in its transaction with Xylem.
Click here to learn how to join the action https://www.ademilaw.com/case/evoqua-water-technologies-corp or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges Evoqua's financial outlook and prospects are excellent and yet Evoqua shareholders will receive only 0.480 shares of Xylem for each Evoqua share, representing a value of $52.89 per share based on Xylem and Evoqua closing prices as of January 20, 2023, reflecting an implied enterprise value of approximately $7.5 billion. The transaction agreement unreasonably limits competing bids for Evoqua by imposing a significant penalty if Evoqua accepts a superior bid. Evoqua insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Evoqua's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Evoqua.
If you own Evoqua common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/evoqua-water-technologies-corp.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-evoqua-water-technologies-corp-has-obtained-a-fair-price-in-its-transaction-with-xylem-301728056.html
SOURCE Ademi LLP
